Zya's $15m sugar reduction tech targets diabetes costs without recipe changes
Zya, a 2018-founded health tech firm, secured $15 million in Series A funding led by Astanor to scale its Convero enzyme technology. This enzyme converts approximately 30% of sucrose in low-moisture foods—like chocolate, cereal bars, and biscuits—into fructooligosaccharides (FOS), a prebiotic fiber. Crucially, the technology avoids reformulating recipes or changing declared sugar content on Nutrition Facts panels, enabling cheaper, accessible sugar reduction in existing products. Zya expects to launch US products with food manufacturers by late 2027 after completing regulatory approvals, including a US GRAS determination by end-2026.
The mechanism relies on precision fermentation to produce the enzyme, which works best in dry foods to prevent premature activation. Zya has validated the technology through 28-day rat studies and genotoxicity assessments but has not yet conducted human clinical trials or made claims about reduced calorie intake or blood glucose response. Current applications are limited to low-moisture foods, excluding yogurt or beverages.
This approach could lower diabetes costs globally by making sugar reduction accessible without recipe changes—a key barrier to affordable health interventions. However, it remains unproven for human health outcomes and faces regulatory hurdles beyond animal studies. What matters now is whether Zya’s partnerships with 100+ food manufacturers can deliver scalable, compliant products before 2027 that actually reduce diabetes risk without altering consumer habits.
What to watch: Completion of human trials, regulatory approvals for US markets, and whether the technology holds up in real-world food processing. Caveats: No human studies yet; enzyme activity may be compromised by thermal processing; regulatory status pending beyond current animal model validation.
Source: AgFunder News
Many Minded